Therapy Areas: Autoimmune
Horizon Therapeutics Expands East Coast Research and Development and Technical Operations Capability
7 January 2022 - - Dublin-based Horizon Therapeutics plc (NASDAQ: HZNP) has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the Alexandria Center at Traville Gateway campus in Rockville, Maryland, the company said.

When completed, the state-of-the-art facility will serve as the company's primary East Coast research and development and technical operations hub.

Construction at the 192,000-square-foot site is underway and Horizon expects to start work on interior improvements in 2023.

Additional terms of the agreement were not disclosed. Horizon is being represented in the transaction by CBRE.

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases.
Login
Username:

Password: